Subject: Baxter Unit's Process In Hemophiliac Care Is Approved by FDA
Date: Published: 2/25/88 34 lines
Source:  WALL STREET JOURNAL. Copyright Dow Jones & Co. Inc. 

   Baxter Unit's Process
   In Hemophiliac Care
   Is Approved by FDA

   DEERFIELD, Ill. -- Baxter Travenol Laboratories Inc. said
its Hyland Therapeutics unit received Food and Drug
Administration approval for an advanced process of making
Hemofil Antihemophilic Factor, which is used in the treatment
of hemophilia.
   The health-care products and services concern said the
process, which uses monoclonal antibodies to extract factor
VIII:  C from plasma, significantly reduces the amounts of the
viruses that cause hepatitis and AIDS. Factor VIII:  C is the
clotting protein missing from the blood of hemophiliacs.
   In addition, the company said it had licensed a
solvent-detergent viral inactivation process from the New
York Blood Center and added this step to its purification
process.  Factor VIII products currently on the market undergo
a heat-treatment process that significantly reduces the risk
of AIDS transmission, but which has been shown to be
ineffective in eliminating hepatitis viruses, particularly
hepatitis non-A and non-B. 
   In New York Stock Exchange composite trading, Baxter
Travenol shares closed at $24.50, unchanged.

[This article is made available here by Dow Jones Co. for the 
personal and non-commercial use of callers to this bbs, in the 
hope that it will be of some help to those who are suffering 
from the disease and others who are seeking to help them.]